The Savior Cells?
April 14, 2016
(Science) – The trial, still being planned, is one of a handful being designed in Europe and the United States for arguably the trickiest patient population there is: pregnant women and their fetuses. After decades of hopes raised and dashed, pediatricians, immunologists, and others are cautiously hopeful that new biological insights and a push for treatment from parents-to-be could turn the tide for prenatal stem cell therapy. “I think [there’s] a lot more of an understanding about what’s feasible, what’s safe, what’s ethical,” says Anna David, who studies fetal therapy at University College London and is collaborating with Semler on the OI trial.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.